Cargando...
Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization
An increasing number of therapeutic antibodies targeting tumors that express the epidermal growth factor receptor (EGFR) are in clinical use or late stages of clinical development. Here we investigate the molecular basis for inhibition of EGFR activation by the therapeutic antibody, matuzumab (EMD72...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2008
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2725356/ https://ncbi.nlm.nih.gov/pubmed/18394559 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccr.2008.02.019 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|